PMID- 27619394
OWN - NLM
STAT- MEDLINE
DCOM- 20170707
LR  - 20181113
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 61
IP  - 11
DP  - 2016 Nov
TI  - Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with 
      Genotype 1 Hepatitis C: A Meta-Analysis.
PG  - 3108-3117
AB  - BACKGROUND: Sofosbuvir and ledipasvir with or without ribavirin (RBV) regimens 
      (SLR vs. SL) have exhibited promising results for the treatment of patients with 
      hepatitis C virus (HCV) genotype 1 infection. AIM: To comprehensively compare the 
      efficacy and safety of the SL and SLR regimen for the treatment of chronic HCV 
      genotype 1 infections. METHODS: The Cochrane Library, PubMed, Web of Science, and 
      EMBASE databases were searched. Only RCTs that compared the efficacy and safety 
      of SL or SLR regimen for the treatment of chronic HCV genotype 1 infection were 
      included. The primary outcome measures were the sustained virological response 
      weeks 12 (SVR12) post-treatment and adverse events (AEs). RESULTS: Seven studies 
      comprising 2601 patients were included. Compared with the SL regimen, SLR yielded 
      a similar probability of having an SVR12 (RR 1.002, 95 % CI 0.998, 1.017, 
      P = 0.780). Based on subgroup analyses, the addition of RBV to the 8-week SL 
      regimen improved the SVR12 rate. However, the SLR regimen for 12 or 24 weeks did 
      not show a superior SVR12 rate regardless of treatment history and the presence 
      or absence of cirrhosis. The pooled incidence of AEs was higher in patients that 
      received the SLR treatment regimen (RR 1.140, 95 % CI 1.095, 1.187, P = 0.000). 
      CONCLUSIONS: The 12-week or 24-week SL regimen with a low incidence of AEs is as 
      effective and well tolerated as the SLR regimen for the treatment of patients 
      with chronic HCV genotype 1 infection.
FAU - He, Qiu-Feng
AU  - He QF
AD  - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of 
      Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The 
      Second Affiliated Hospital, Chongqing Medical University, NO76 Lin Jiang Road, Yu 
      Zhong District, Chongqing, 400010, China.
FAU - Zhang, Qiong-Fang
AU  - Zhang QF
AD  - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of 
      Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The 
      Second Affiliated Hospital, Chongqing Medical University, NO76 Lin Jiang Road, Yu 
      Zhong District, Chongqing, 400010, China.
FAU - Zhang, Da-Zhi
AU  - Zhang DZ
AD  - Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of 
      Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The 
      Second Affiliated Hospital, Chongqing Medical University, NO76 Lin Jiang Road, Yu 
      Zhong District, Chongqing, 400010, China. dzhzhang@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160912
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fluorenes)
RN  - 013TE6E4WV (ledipasvir)
RN  - 49717AWG6K (Ribavirin)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Benzimidazoles/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Fluorenes/*therapeutic use
MH  - Genotype
MH  - Hepacivirus/genetics
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Ribavirin/*therapeutic use
MH  - Sofosbuvir/*therapeutic use
MH  - Sustained Virologic Response
MH  - Treatment Outcome
PMC - PMC5067290
OTO - NOTNLM
OT  - Efficacy
OT  - Genotype 1 hepatitis C
OT  - Ledipasvir
OT  - Ribavirin
OT  - Safety
OT  - Sofosbuvir
COIS- The authors declare that they have no conflict of interest.
EDAT- 2016/10/19 06:00
MHDA- 2017/07/08 06:00
PMCR- 2016/09/12
CRDT- 2016/09/14 06:00
PHST- 2016/04/14 00:00 [received]
PHST- 2016/08/23 00:00 [accepted]
PHST- 2016/10/19 06:00 [pubmed]
PHST- 2017/07/08 06:00 [medline]
PHST- 2016/09/14 06:00 [entrez]
PHST- 2016/09/12 00:00 [pmc-release]
AID - 10.1007/s10620-016-4291-2 [pii]
AID - 4291 [pii]
AID - 10.1007/s10620-016-4291-2 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2016 Nov;61(11):3108-3117. doi: 10.1007/s10620-016-4291-2. Epub 2016 
      Sep 12.